BLU Investor Update: Bronstein, Gewirtz & Grossman, LLC Noti

|Jul 10|magazine4 min read

NEW YORK, July 10, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU). Investors who purchased BELLUS securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:              

The investigation concerns whether BELLUS and certain of its officers and/or directors have violated federal securities laws.

On July 6, 2020, BELLUS announced the results of its Phase 2 RELIEF trial for BLU-5937 and revealed that it failed to reach its primary endpoint of a statistically significant reduction in awake coughs, and that its drug failed to outperform a placebo. Following this news, BELLUS stock dropped roughly 70% on July 6, 2020.

If you are aware of any facts relating to this investigation, or purchased BELLUS shares, you can assist this investigation by visiting the firm's site: You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Cision View original content to download multimedia:

SOURCE Bronstein, Gewirtz & Grossman, LLC